• Profile
Close

Tolerability and effectiveness of exenatide once weekly relative to basal insulin among type 2 diabetes patients of different races in routine care

Diabetes Therapy Oct 09, 2017

Nunes AP, et al. - This study used real-world electronic health record (EHR) data to test exenatide once weekly (EQW) for overall efficacy and tolerability in racial/ethnically diverse patients with type 2 diabetes and results were also compared with those who received basal insulin (BI), taking into account race. Findings revealed that treatment with EQW versus BI was related to larger reductions in HbA1c and weight and reduced risk of hypoglycemia. Notably, these effects did not vary between white and African American patients.
Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay